Recent US efforts to introduce Most Favored Nation (MFN) drug pricing are creating new layers of uncertainty for transactions involving the commercialization of prescription…
In brief On May 18, 2026, the U.S. Department of Health and Human Services Office of Inspector General (“OIG”) released an unfavorable Advisory Opinion…
On April 2, 2026, President Trump issued a proclamation adjusting imports of patented pharmaceuticals and associated pharmaceutical ingredients, including active pharmaceutical ingredients (APIs). The action followed…